06 Apr Non-Small-Cell Lung Cancer: New Agent Effective Against EGFR TKI Resistant Cancer
MedicalResearch.com: What are the main findings of the study?
Dr. Wakalee: CO-1686, with the new hydrobromide formulation, has been active at multiple dose levels (500, 750 or 1000 mg orally twice daily). The response rate in patients with EGFR mutant (non-small-cell Lung Cancer) NSCLC that has progressed after therapy with EGFR TKI, and has centrally confirmed T790M, is 64% per RECIST. The majority of responses are ongoing at the time of this report. The drug has been overall very well tolerated.
MedicalResearch.com: Were any of the findings unexpected?
Dr. Wakalee: We are excited to see the high rate of response in patients with T790M. Unexpectedly we noted a toxicity of hyperglycemia in approximately a quarter of patients. The hyperglycemia was unexpected as it was not seen in animal models and work is being done to understand the mechanism of this toxicity. Now that we are aware of this issue it has been relatively easy to monitor and manage with oral hypoglycemic agents.
MedicalResearch.com: What should clinicians and patients take away from your report?
Dr. Wakalee: CO-1686 is an exciting compound with demonstrated activity in EGFR mutant non-small-cell Lung Cancer (NSCLC )with T790M and trials are ongoing to clearly establish the optimal dose and establish duration of response.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Dr. Wakalee: The TIGER trials in development will explore the drug as an option for patients whose tumor has progressed after first line EGFR TKI therapy and as a first line agent (phase III trial versus first line erlotinib) and will further explore different methods to test for T790M.
First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosne kinase inhibitor of mutations of EGFR (activating and T790M).